IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.51
+1.00%Margins
Gross margin
97.1%
EBITDA margin
-7590.1%
EBIT margin
-7877.5%
Net margin
-7585.9%
FCF margin
-5839.5%
-73.2%
Return on equity
-63.1%
Return on assets
-76.0%
Return on invested capital
0.01x
Asset turnover
-$414.3M
Cash from operations
$3.86
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026